Objective: To identify novel causes of recessive ataxias, including spinocerebellar ataxia with saccadic intrusions, spastic ataxias, and spastic paraplegia. Methods: In an international collaboration, we independently performed exome sequencing in 7 families with recessive ataxia and/or spastic paraplegia. To evaluate the role of VPS13D mutations, we evaluated a Drosophila knockout model and investigated mitochondrial function in patient-derived fibroblast cultures. Results: Exome sequencing identified compound heterozygous mutations in VPS13D on chromosome 1p36 in all 7 families. This included a large family with 5 affected siblings with spinocerebellar ataxia with saccadic intrusions (SCASI), or spinocerebellar ataxia, recessive, type 4 (SCAR4). Linkage to chromosome 1p36 was found in this family with a logarithm of odds score of 3.1. The phenotypic spectrum in our 12 patients was broad. Although most presented with ataxia, additional or predominant spasticity was present in 5 patients. Disease onset ranged from infancy to 39 years, and symptoms were slowly progressive and included loss of independent ambulation in 5. All but 2 patients carried a loss-of-function (nonsense or splice site) mutation on one and a missense mutation on the other allele. Knockdown or removal of Vps13D in Drosophila neurons led to changes in mitochondrial morphology and impairment in mitochondrial distribution along axons. Patient fibroblasts showed altered morphology and functionality including reduced energy production. Interpretation: Our study demonstrates that compound heterozygous mutations in VPS13D cause movement disorders along the ataxia-spasticity spectrum, making VPS13D the fourth VPS13 paralog involved in neurological disorders. A taxia is a symptom of >400 syndromic neurological conditions or can be the sole symptom of >80 recessively, dominantly, or X-linked inherited genetically defined conditions. 1-3 Recessive forms of ataxia are clinically and genetically more heterogeneous than dominant ataxias. Only in a minor fraction (20%) of idiopathic or suspected recessive ataxia cases can a mutation in a known ataxia gene be identified, 4 suggesting that much of the genetic heterogeneity still remains to be discovered. In addition to heterogeneity, there is also pleiotropy, as the spectrum of ataxias also includes clinical and molecular overlap with, for example, the spastic paraplegias.
A taxia is a symptom of >400 syndromic neurological conditions or can be the sole symptom of >80 recessively, dominantly, or X-linked inherited genetically defined conditions. [1] [2] [3] Recessive forms of ataxia are clinically and genetically more heterogeneous than dominant ataxias. Only in a minor fraction (20%) of idiopathic or suspected recessive ataxia cases can a mutation in a known ataxia gene be identified, 4 suggesting that much of the genetic heterogeneity still remains to be discovered. In addition to heterogeneity, there is also pleiotropy, as the spectrum of ataxias also includes clinical and molecular overlap with, for example, the spastic paraplegias. 5 Here, we report 12 patients from 7 families with compound heterozygous mutations in VPS13D. All patients > 2 years old have ataxia and/or spasticity, whereas the one 2-year-old patient shows developmental delay and hypotonia and is nonambulatory (see Supplementary  Table) . The phenotype in 1 of these families, comprising 5 patients (Fig 1) , has previously been described in detail. 6, 7 Briefly, patients in this family demonstrated early adult onset cerebellar ataxia with neuropathy and pyramidal signs, as well as striking saccadic intrusions, hence initially referred to as spinocerebellar ataxia with saccadic intrusion (SCASI), 6 later renamed spinocerebellar ataxia, recessive, type 4 (SCAR4). Analysis of Drosophila knockout models and patient-derived fibroblasts suggests that mutations in this new ataxia/spasticity gene impact on mitochondrial structure and function.
Materials and Methods

Patients
Patients were identified in 5 different centers with a focus on movement disorders located at Case Western Reserve University (Cleveland, OH) and genetically analyzed in Ann Arbor (MI, UM1), Nijmegen and Rotterdam (the Netherlands, NIJ1-4), L€ ubeck (Germany, LUB1), and Winston-Salem (NC, USA, WF1). Diagnostic testing (including gene panel analysis of known ataxia/spasticity genes) did not reveal a molecular diagnosis in these cases. All patients and relatives gave written informed consent to participate in diagnostic or research studies that were approved by the respective local institutional review boards (Institutional Review Boards of the University of Michigan Medical School, University of L€ ubeck ethics review panel), or to local (NIJ and Rotterdam) or commercial (WF1; GeneDx, Gaithersburg, MD) clinical exome sequencing (NIJ and WF1). Formation of this collaboration was facilitated by publication of grants funded by the National Ataxia Foundation and by GeneMatcher. 8 
Genetic Studies: Linkage Analysis and Exome Sequencing
In Family UM1, linkage analysis was performed with DNA from all 5 affected members, the mother, and 7 unaffected siblings using the Infinium HumanLinkage-24 Beadchip kit (6,000 markers, WG-32-140; Illumina, San Diego, CA), followed by parametric fully penetrant recessive model analysis in Merlin. 9 In all families, whole exome sequencing was performed by exome capture (UM1: SeqCap EZ Exome Kit v3.0 [Roche Sequencing, Pleasanton, CA] at UM core facility; LUB1: NexteraRapid Exome Capture Kit [Illumina] at Centogene [Rostock, Germany]; all NIJ cases and WF1: SureSelectXT Human All Exon 50Mb Kit V5 [Agilent Technologies, Santa Clara, CA] at BGI Copenhagen [NIJ] and at GeneDx [WF1]) followed by next generation sequencing on Illumina arrays (UM1 and LUB1: paired end HiSeq2000; LUB1: NextSeq500) to medium coverage of 46 3 (UM1) or to 75 3 (all NIJ, LUB1, and WF1).
For UM1, 2 cases were sequenced and variant analysis was restricted to the 10Mb linkage region. For LUB1, WF1, and NIJ4, parents were also sequenced and initially, a trio analysis for de novo variants (no damaging hits) was performed. Variants were called as follows. For UM1.1 and UM1.4, alignment was done using Burrows-Wheeler Aligner against Human 1K Genome reference, duplicates were removed using Picard (v1.74), base recalibration, realignment, and variant calling were done using GATK (v3.3); these samples were part of a 734-sample pooled call. For LUB1, variant calling was performed as described. 10 For NIJ, clinical exome sequencing and variant calling were performed as described. 11 For WF1, GeneDx clinical whole exome pipeline was employed. Detected variants were filtered for rare (European population frequency < 0.01) and protein-changing variants under a recessive model. VPS13D variants emerged as the strongest candidate in all cases. All VPS13D variants were Sanger confirmed and segregation in the family consistent with compound heterozygosity was verified.
Copy number variant analysis was not performed on all samples. Because single exonic deletions are difficult to detect in whole exome analyses, they cannot be ruled out. Because all patients were compound heterozygous, a whole gene deletion in VPS13D can be ruled out.
Analysis of Expression: Nonsense-Mediated Decay and Splice Site Prediction
Because VPS13D expression is higher in skin (fibroblasts) than in blood, we used mRNA extracted from a fibroblast culture to study expression levels and nonsense-mediated mRNA decay (NMD) in Family UM1 (data not shown) and Patient LUB1.1. For Patient LUB1.1, RNA was extracted using the QIAmp RNA Extraction Kit (Qiagen, Germantown, MD). Oligo-dTnucleotides of the Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA) served as primers to synthesize the complementary DNA (cDNA) by use of reverse transcriptase (RT). Polymerase chain reaction (PCR) was performed with primers in exons 21 and 22 (VPS13Dex21F: TGATTCCTTAGTCCA CATCAAC; VPS13Dex22R: ATCATTTCCAGGTGTGC TAC), and the respective product was inspected for its size and Sanger sequenced. Furthermore, the expression of VPS13D in LUB1.1 and a control was compared to the expression of ß -actin, HPRT, and YAZ, which served as reference genes. These quantitative PCRs were performed with SYBR Green on the LightCycler 480 system (Roche Molecular Systems; data not shown). Because both quantitative PCR and sequencing indicated instability of the allele with the nonsense mutation, we treated fibroblasts of LUB1.1 with cycloheximide for 8 hours at 100 lg/ml final concentration to stabilize the transcript and confirm -NMD-as the cause. The effect of cycloheximide was evaluated by sequencing of cDNA.
In addition to nonsense and missense mutations, we detected 3 variants at splice sites (c.941 1 3A>G, c.2237-1G>C, c.9998 1 4A>C). Because we are limited in performing skin biopsy for research purposes to adults only, per our institutional review board, we do not have fibroblast cultures from the children with splice mutations. Instead, we used 2 online slice site prediction tools to estimate the impact of these variants on splicing: Human Splicing Finder (HSF; http://www. umd.be/HSF3/) 12 and Splice Site Prediction (SSP; http://www.
fruitfly.org/seq_tools/splice.html), set to mammals. HSF provides a consensus value (CV) variation as output with the interpretation of CV < 210% indicating a disruption of the splice site. SSP generates a score between 0 and 1, with a score of 0.5 recognizing about 90% of the actual sites and a falsepositive rate of < 5%. The higher the score, the higher the probability that the splice site is active.
Comparison of Mutation Frequencies in VPS13D Paralogs
To assess the impact of the loss of function of each VPS13 paralogs, we compared phenotypes of animal models available in the literature and in databases and examined estimates of mutation frequencies in humans. To assess the common mutation types (eg, loss of function, missense) in each VPS13 paralog-associated disease, we restricted analysis to cases in which both mutations are known.
Functional Studies in Patient-Derived Fibroblasts
From the UM1 family, we established fibroblast cell lines from 2 patients (UM1.2 and UM1.4) and 2 controls (UM1.17, a daughter of an affected, and UMCtrl1, a married-in unaffected spouse). From LUB1, fibroblast lines were established from LUB1.1, the index patient, and her heterozygous parents (LUB1.3 and LUB1.4). In addition, fibroblasts from 2 unrelated control lines (LUBCtrl1, also known as L-2132; LUBCtrl2, also known as L-2134) were used. For mitochondrial imaging in fibroblast from the UM1 family, MitoTracker Red CMXRos (Invitrogen, Carlsbad, CA) was applied to fibroblasts cultured on coverslips for 40 minutes before fixing in 4% formaldehyde for 12 minutes. Through a PLAPON 60 3 (1.42 Oil) lens on an Olympus (Tokyo, Japan) FV1000 confocal microscope, 6 to 8 Z stacks of images were obtained per visual field to produce images of in total approximately 72 to 127 cells per line. Images were flattened using Zprojection at maximum intensity using the open software Fiji, 13 which was also used to generate intensity histograms. For each 2-dimensional image, the Otsu algorithm was applied to extract the top 1% brightest pixels. To quantify spherical mitochondria, any areas smaller than 1.5 mm 2 and with less circularity than 0.18 were removed using Fiji's Analyze Particles function. The remaining selected areas correspond to bright and spherical mitochondria. The average number of such selected objects per cell was calculated in each cell line. We also computed the percentage of cells with >2 such objects in the perinuclear region. Form factor analysis as a measurement of the mitochondrial network integrity was performed by using a selection algorithm in the software program Volocity (PerkinElmer, Waltham, MA) to select mitochondrial objects (1 standard deviation above the mean MitoTracker intensity) of a projected z stack image (average intensity). For each projected image containing 4 to 12 cells, form factor, defined as ½P 2 m =½4pA m with P m being the perimeter and A m being the area of a mitochondrion, was calculated for all selected mitochondria, and the mean was obtained for the entire image field. For each individual, 11 to 17 images from 2 independent experiments were analyzed.
In fibroblasts of Family LUB1, the form factor was determined as previously described.
14 In brief, the mitochondrial network in fibroblasts was stained with an anti-GRP75 antibody (1:1,000; Abcam, Cambridge, MA) in combination with the Zenon immunolabelling kit (Invitrogen) according to the manufacturer's protocol. Based on single cell images, mitochondria area and outline were measured and the form factor was calculated. Mean form factor was averaged over 20 cells per individual.
Measurement of the Rate of Adenosine Triphosphate Synthesis in Cultured Fibroblasts
Adenosine triphosphate (ATP) was quantified, in triplicate, using the ATP Bioluminiscence Assay Kit CLS II (Roche Diagnostics, Mannheim, Germany) following the manufacturer's instructions. ATP was measured in a luminometer (Berthold Detection Systems, Pforzheim, Germany), and calculated as ATP generated (micromoles) per minute per milligram of protein. The amount of protein was determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). only #56282 homozygous shown), Vps13D RNA interference (RNAi; #38320), motoneuron-specific Gal4 driver (D42-Gal4, #8816), a deficiency line Df(3L)Exel6117 (#7596), and fluorescent mitochondrial marker (UAS-mitoGFP, #42727). 15 All phenotypes observed of homozygous Vps13D mutant alleles were confirmed in compound heterozygous flies of the 2 alleles, and in mutant alleles over the deficiency line, which lacks a defined region of the Drosophila chromosome containing the entire Vps13D genetic locus and some neighboring genes. For staining, we used the following primary antibodies: ATP5A (Abcam ab14748), green fluorescent protein (GFP; Life Technologies, Carlsbad, CA; A-11122, 1:1,000), horseradish peroxidase (Jackson ImmunoResearch, West Grove, PA; 123-605-021, 1:1,000), and discs large (Dlg1) (Developmental Studies Hybridoma Bank, Iowa City, IA; 4f3, 1:1,000). All secondary antibodies were from Invitrogen (Alexa-conjugated 1:1,000, 2 hours, RT). Standard dissection and immunostaining procedures were used for larval tissue analysis. 16 For larval immunostaining, tissues were fixed with 4% formaldehyde for 20 minutes at room temperature prior to staining, except for anti-ATP5A staining, in which tissue was fixed with Bouin fixative for 7 minutes at room temperature. Form factor analysis of larval ventral nerve cords was performed using Volocity to select mitochondrial networks in the cell bodies of RNAi expressing motoneurons based on threshold of mitoGFP fluorescence (2.5 standard deviations above the mean fluorescence intensity) from a projected z stack image. For each cell body, an average form factor of all mitochondria was calculated.
Functional Studies in Drosophila Models
Statistical Analyses
Differences were analyzed statistically using unpaired t tests, or analysis of variance with a Bonferroni-Dunn post hoc correction.
Results
Genetic Findings
OVERVIEW. In 4 different locations in the USA and Europe, we independently detected compound heterozygous VPS13D mutations in 7 families. The mutational spectrum included 5 nonsense, 5 missense, 1 frameshift, 1 essential, and 2 nonessential splice site mutations (Table 1) . All families carried a combination of 1 loss-of-function (LOF) mutation (nonsense, frameshift, or essential splice sites) and 1 presumably milder change (missense or nonessential splice site mutation). All variants were absent or extremely rare (<13 heterozygous carriers) in the 120,000 individuals listed in gnomAD. Among the 5 missense mutations, Gly1190Asp and Met1307Ile, found in families UM1 and NIJ1, were located in the center of the protein.
The three C-terminal missense mutations detected in families LUB1, NIJ2, and NIJ3 are close to or within the C-ANNALS of Neurology domain (see Fig 1D) , which is conserved and unique among all VPS13 proteins including yeast.
UM1 ATAXIA FAMILY (SCAR4).
We have previously reported a family with 14 siblings, 5 of whom had adult onset spinocerebellar ataxia with saccadic eye intrusion (see Fig 1A; SCAR4 6, 7 . After exclusion of known ataxia mutations, genome-wide linkage analysis under a recessive, full penetrance model identified only a single locus with logarithm of odds (LOD) > 0, which was 20cM/ 10Mb on chromosome 1p36 flanked by rs7538691 and rs761162 (LOD 5 3.1, data not shown). Whole exome sequencing in 2 affected individuals revealed compound heterozygous mutations in VPS13D as the only likely genetic cause within the linked region. The variants comprised a paternally inherited missense change (c.3569G>A, p.Gly1190Asp) and a maternally inherited nonsense mutation (c.3316C> T, p.Gln1106Ter). Sanger sequencing verified segregation among all 12 siblings with available DNA samples. Sequencing of RT-PCR products from fibroblast cell lines of 2 patients demonstrated that the nonsense allele-containing mRNA product was less abundant, suggesting that it Coordinates of all detected mutations are based on NM_015378 for cDNA and GRCH37/hg19 built for genomic DNA. CADD score and MutationTaster are in silico prediction of deleteriousness of each mutation. Three of the mutations have been reported previously in public exome/ genome databases (gnomAD: genome aggregation consortium at http://gnomad.broadinstitute.org/gene/ENSG00000048707). For splice variants, splice site prediction scores were calculated at Human Splicing Finder (http://www.umd.be/HSF3/) and Splice Site Prediction (http://www.fruitfly. org/seq_tools/splice.html). CADD 5 Combined Annotation Dependent Depletion; NA 5 no assessment.
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Month 2018underwent NMD (data not shown). Gly1190Asp introduces an extra negative charge and appears not to affect protein stability (data not shown).
FAMILY LUB1. In 2 affected sisters of a German family with spastic ataxia (see Fig 1B) , we detected compound heterozygous mutations in VPS13D including a maternal nonsense mutation (Tyr1803Ter) and a paternal missense change (Ala4210Val, rs746736545). Similar to Family UM1, sequencing of cDNA of the index patient revealed the allele with the nonsense mutation to be less abundant. Treatment with cycloheximide stabilized the mutated allele and confirmed that the nonsense-mutated allele underwent NMD (see Fig 1C) . NMD resulted in a decreased expression level of about 50 to 60% in Patient LUB1.1 (data not shown).
ADDITIONAL SPORADIC CASES. At the Radboudumc Expert Centre for genetic movement disorders in Nijmegen, and the genetic movement clinic in Rotterdam, the Netherlands, 4 unrelated cases of different ethnicities with compound heterozygous VPS13D mutations were independently identified (see Supplementary Table) . NIJ1 and NIJ2 carry a combination of a nonsense mutation and a missense change, NIJ3 carries a frameshift and a nonessential splice site mutation, and NIJ4 carries an essential splice site mutation and a missense change. NIJ4 also has optic atrophy and carries a heterozygous frameshift mutation in OPA1 (c.1156_1157del [p.Leu386Glufs*2]). A second (biallelic) mutation in OPA1 was excluded by exome sequencing with sufficient coverage of the entire coding region and splice sites. Her mother carried the same variant and has isolated optic atrophy. At the Wake Forest School of Medicine, WinstonSalem, North Carolina, 1 additional case, WF1, was identified by clinical exome sequencing (GeneDx). WF1 displayed hypotonia, balance and coordination difficulties, and global developmental delay; more formal clinical ataxia tests were difficult to perform, due to her current age and disease features as well as global developmental delay. WF1 has a combination of a nonsense mutation and a nonessential splice site change.
To estimate the impact of the splice site changes on the transcript, we used 2 different in silico splice site prediction programs. As expected, both programs, HSF and SSP, strongly predicted an effect on splicing of the variant at the invariant acceptor splice site of intron 18 in NIJ4, c.2237-1G>C (see Table 1 ), which hence was classified as LOF. The splice region variants in NIJ3 and WF1, however, are not within invariant splice consensus sites. For c.9998 1 4>C in intron 49, CV variation was 210.57%, just below HSF's 210 cutoff. SSP's prediction score dropped from 0.93 to 0.62, suggesting a mild, if any, impact on recognition of this splice site. For c.941 1 3A>G in intron 9, the CV variation was 20.83% by the HSF algorithm and would argue against an effect on splicing. However, the SSP score dropped from 0.89 to 0.21, suggesting reduction in predicted splicing ability. These 2 nonessential splice site mutations are hence not considered complete LOF alleles, as they may allow some correctly spliced transcripts. Confirmatory analysis of intronic splice region variants could not be performed at this time (see Materials and Methods for details).
Clinical Findings
All cases except for WF1, which was too young, had either ataxia or spasticity as a core symptom. Onset ranged from infancy to adulthood. The UM1 family, previously designated as SCAR4, demonstrated primarily adult onset ataxia with distinct macrosaccadic intrusions, 7 with pyramidal features, neuropathy, and myoclonus but no intellectual disability. 6 Videos of the clinical examinations and the distinct eye phenotype are available in the online supplement of Swartz et al. 7 The 2 sisters from Family LUB1 were similar to UM1 in their onset and clinical phenotypes, except for a different oculomotor phenotype. By contrast, NIJ1 had a much earlier onset (<5 years) and symptoms were more debilitating (wheelchair-bound by age 17 years). Whether his phenotypic difference originates from more severe VPS13D mutations or other environmental or genetic factors is unknown at this time. Similarly, NIJ4 and WF1 were severely affected with an age at onset in the first year of life. In addition to ataxia and neuropathy, NIJ4 suffers from developmental delay, seizures, and optic atrophy.
Coincidentally, she carries an additional mutation in OPA1 (optic atrophy 1/ mitochondrial dynamin-like GTPase), which explains the optic atrophy but not the additional seizures and the developmental delay. NIJ2 was affected by spastic paraplegia without ataxia, with onset in early adulthood. Patients WF1 and NIJ3 might be more severely affected due to 2 severe mutations including a nonessential splice site change and an LOF mutation, in contrast to the combination of a missense and an LOF mutation in the other subjects.
Among VPS13 Paralogs, VPS13D Is the Most Intolerant to Mutations
Yeast vps13 is implicated in many cellular functions including sporulation, Golgi organization, and mitochondrial integrity. 17 During metazoan evolution, 2 duplication events gave rise to 3 paralogs: VPS13A/C, B, and D. Drosophila Vps13 (CG2093) is an ortholog of VPS13A/ C, which further duplicated in the vertebrate evolution into VPS13A and VPS13C (updated from Velayos-Baeza et al 18 ). Because not much is known about VPS13D-specific function, we compared reported phenotypes of VPS13 homologs in the 2 model organisms fly and mouse (fly: CG2093 19 ; mouse: MGI2444304, 20 MGI2444207, and MGI2448530; Table 2 ). Mutations in Vps13D/VPS13D cause embryonic lethality in both animals, whereas mutations in VPS13A and C appear more tolerable during early development (animal phenotypes for VPS13B are unavailable). A similar trend was observed in human populations (see Table 2 ). Residual Variation Intolerance Score (RVIS) is a gene-based intolerance score derived from allele frequency in whole exome sequence data. 21 Among the paralogs, VPS13D has the lowest RVIS score of 24.23, 0.14 percentile, suggesting that VPS13D is among the most mutation-intolerant of human genes. We also compared the frequency of LOF in each paralog in the Exome Aggregation Consortium (ExAC) browser. Again, VPS13D emerges as most sensitive to LOF mutations, with the lowest ratio of the number of variants observed over expected. For VPS13D, the probability of LOF intolerance (pLI) score is 1, virtually certain. Chorea acanthocytosis is caused in 29 of 31 cases by LOF/LOF mutations in VPS13A, 22 Cohen syndrome in 41 of 45 cases by LOF/ LOF mutations in VPS13B, [23] [24] [25] [26] [27] and Parkinson disease in 3 of 4 cases by LOF/LOF mutations in VPS13C cases. 28, 29 In summary, VPS13D is intolerant to complete LOF of both alleles, being likely incompatible with life, consistent with our finding of only compound heterozygous missense/LOF or nonessential splice/LOF mutations.
Vps13D Disruption in Drosophila Is Lethal and Causes Mitochondrial Defects
Known also as CG32113 in flies, fly Vps13D shows 33% protein identity to the human gene (see Table 2 ). Consistent with Vps13d lethality in mice, flies disrupted for Vps13D do not survive beyond the 2nd instar larvae stage. This lethality was confirmed with 2 independent lines containing large insertions in the coding region of Vps13D, including compound heterozygous animals containing 1 copy of each Vps13D allele, hence ruling out secondary mutations as the cause of lethality. While we observed no obvious defects in markers for Golgi, endoplasmic reticulum, lysosomes, and the nucleus (data not shown), we observed that deletion of Vps13D led to severe alterations in mitochondrial morphology. In early 2nd instar larvae before lethality, instead of forming fine mitochondrial networks in individual cells, mitochondria appear as singular, enlarged objects. This abnormal mitochondrial appearance was present in the larval brain (see Fig 2A) and other tissues in these young larvae (not shown).
We then used RNAi-mediated knockdown 30 to inhibit expression of Vps13D specifically in motoneurons. This allows for survival of larvae to the 3rd instar stage (death at pupal stage), which enables further characterization of Vps13D's autonomous function in neurons. By coexpression of mitoGFP targeted specifically to Residual Variation Intolerance Score (RVIS) is a mutation intolerance score (more negative, more intolerant) and its percentile rank in all human genes is given in parenthesis (lower, more intolerant). %ExAC v2 RVIS is RVIS v4, constructed on ExAC v2 (gnomAD) release. LoF (Loss of function) represents stop-gained and essential splice site mutations as defined in ExAC. LoF O/E represents the ratio of the number of variants observed over expected. LoF pLI is the probability of LoF Intolerance (pLI >50.9 regarded as extremely LoF intolerant mitochondria of the RNAi-depleted neurons, 15 we observed enlarged spherical mitochondria (see Fig 2B) . Compared to a control RNAi line targeting luciferase, knockdown by Vps13D RNAi resulted in a significant reduction in quantified form factor (see Fig 2C) , consistent with a loss of complexity of the mitochondria network coinciding with enlarged, isolated mitochondria. These observations suggest a role for Vps13D in regulating mitochondrial morphology and potentially also mitochondrial function in neurons. The abnormal mitochondrial network in neuronal cell bodies led us to hypothesize that loss of Vps13D would deleteriously impact the distribution of mitochondria to distal regions of neurons.
Previous studies have linked deficiencies in mitochondrial trafficking to distal neurites in neurodegenerative diseases and neuropathies. 31, 32 We observed that reduction of Vps13D in motoneurons led to strong impairment in the distribution of mitochondria in peripheral axons in segmental nerves and neuromuscular junction synapses (Fig 3) . The density of mitochondria was progressively reduced concomitant with increased distance from the cell body locations in the central nervous system. This failure to distribute mitochondria resembles previously described defects for mutations in mitochondrial fission/fusion machinery. 31 
Patient-Derived Fibroblasts Show Altered Mitochondrial Morphology
Given these fly data, we also investigated mitochondrial function and morphology in human fibroblasts. Staining fibroblasts from the affected subjects of family UM1 with MitoTracker, which accumulates in mitochondria in a membrane potential-dependent manner, revealed significantly brighter mitochondria (Fig 4) . Whereas the typical mitochondrial network of elongated objects and branches was observed in both control and patient cells, the perinuclear regions of only affected cells often contained unusually bright and significantly more spherical mitochondrial objects, which were mostly in clusters and at higher magnification appeared to be donut-shaped. To quantify the abundance of the bright and spherical mitochondria in each cell line, we extracted the top 1% brightest pixels from each image and selected circular objects based on computed circularity score. The average number of such abnormal mitochondrial objects was 6-fold higher in the affected compared to control cells. In the perinuclear region, such objects were identified in clusters (3) in 10% of normal but 91% and 67% of fibroblasts of affected subjects' cells. Consistent with the Drosophila data, form factor analysis also revealed a significant reduction in the degree of mitochondrial branching in the affected fibroblasts compared to controls. These observations suggest structural defects in mitochondria in VPS13D-deficient fibroblasts. Independent analysis of fibroblasts of the proband of family LUB1 demonstrated that the affected fibroblasts expressed reduced levels of mitochondrial GRP75 protein compared to controls (Fig 5) . Form factor analysis of GRP75 immunostaining revealed a similar reduction in the degree of mitochondrial branching of proband fibroblasts compared to 2 unrelated healthy controls. These structural mitochondrial changes were accompanied by a reduced ATP production rate of LUB1.1 compared to control fibroblasts.
Discussion
In this study, we have identified 7 different compound heterozygous mutations in VPS13D in 12 patients and have linked VPS13D/Vps13D defects in patient fibroblasts and in flies to mitochondrial deficits. Our study also included a large family with ataxia (SCAR4) and linkage to a 10Mb region on chromosome 1p36 harboring the VPS13D gene.
The core phenotype of the 11 patients older than 2 years with compound heterozygous VPS13D mutations is characterized by movement disorders of the ataxia-spasticity spectrum, ranging from predominant ataxia, spastic ataxia, to spastic paraplegia without ataxia, and ataxia plus phenotypes. The latter included 2 cases with an additional developmental delay phenotype (NIJ3 and NIJ4). The youngest patient, WF1 of age 2 years at the last evaluation, presented with hypotonia and developmental delay, including motor delay, and was not yet ambulatory. These 3 patients also have different types of or additional mutations, as NIJ3 and WF1 carry nonessential splice region variants in addition to an LOF. This may be more severe than the combination of missense/LOF found in the other cases. In addition, NIJ4's presentation may be complicated by an additional mutation in OPA1. The protein encoded by OPA1 is also implicated in mitochondrial function. It is conceivable that there may be an interactive effect of the 2 mutated genes linked to mitochondrial dysfunction. Interestingly, recent data have shown that about 5% of patients carry 2 independent Mendelian diseases. 33 However, digenic inheritance cannot be ascertained based on this single case. Of note, homozygous or compound heterozygous OPA1 mutations cause an extended multisystem phenotype that includes ataxia and spastic paraplegia, known as Behr syndrome. 34 Although there was complete coverage of the OPA1 coding regions and splice sites, no second mutation in the OPA1 gene was detected by exome nor by copy number analyses (conducted as described). 35 Hence, although we cannot exclude an undetected intronic or promoter mutation that is not penetrant, as the father does not have optic atrophy, we believe Behr syndrome as an alternative diagnosis in this case is not likely.
The overlap between genetic forms of ataxias and hereditary spastic paraplegias is well recognized, as there are other examples of genes (eg, SPG7) that when mutated can give rise to either pure ataxia or spastic paraplegia or to a mixed phenotype of spastic ataxia, 36, 37 developmental delay, and seizures, and other complex phenotypes commonly accompany early onset recessive ataxias. 2 In addition, there was variability in age of onset in our patients, which is also not unusual for ataxias. Frequently observed neurological comorbidities in our series included peripheral axonal neuropathy and extrapyramidal signs such as myoclonus and dystonia. Infertility was noted in 2 male cases. Although it is currently uncertain whether this is VPS13D-related, infertility is a known feature of mitochondrial disease.
38
VPS13D encodes a large protein (4,388 amino acids), whose paralogs cause other neurological disorders; VPS13A mutations cause chorea acanthocytosis, characterized by a severe hyperkinetic movement disorder, myopathy, epileptic seizures, cognitive decline, and behavioral changes, 22 28 Most of these disease-associated mutations are LOF/LOF (see Table 2 ). In contrast to the other VPS13 paralogs, knocking out VPS13D's homologs in Drosophila (our results) and mouse (MGI:2448530) leads to embryonic lethality, and not a single LOF/LOF mutation was identified, suggesting that some residual VPS13D function in humans may be critical for survival. In addition, the ExAC server's pLI score, that is, the probability that a gene may be intolerant to haploinsufficiency, for VPS13D is 1, in contrast to all other VPS13 genes (see Table 2 ). 42 We did not, however, observe the predicted intolerance to haploinsufficiency, as 1 parent of each of the cases reported here was haploinsufficient, but none was symptomatic, including 1 parent who lived into their 90s without apparent neurological problems. Our genetic data allow for some first, yet cautious speculations on genotype-phenotype correlations. First, our current data collectively point to missense/LOF mutations tending to cause relatively pure ataxia and/or spasticity. Second, as suggested by the more severe NIJ3 and WF1 cases, who carry nonessential splice site/LOF mutations, other mutation type combinations may be associated with a broader and/or more severe spectrum of phenotypes. Lastly, the other severe case, NIJ4, had a coexistent dominant OPA1 mutation and corresponding optic atrophy, 43 which was also observed in the subject's mother. The OPA1 mutation may contribute epistatically to the phenotype, as OPA1 also affects mitochondrial function. 43 Although our study convincingly establishes missense/LOF mutations in VPS13D as causing ataxia/spastic paraplegia and mitochondrial pathology, many questions remain to be addressed. Clinically, predicting the phenotype from new mutations in VPS13D will be difficult. Even for missense/LOF mutation carriers, the clinical presentation varied in our series. In addition, homozygous or compound heterozygous missense mutations were not observed here. As VPS13D is a large gene with many missense variants reported in databases including homozygosity, 42 it will be even more difficult to predict pathogenicity of any novel biallelic missense variants. Although further work is warranted to pin down the precise mitochondrial defect, we have shown abnormal mitochondrial morphology in both flies and patient cell lines, and reduced mitochondrial function in fibroblasts. Mitochondrial dysfunction is associated with several other ataxias and spastic paraplegias such as Friedreich ataxia, 44 SCA28, 45 POLG, 46 and SPG7, 47 as well as in some unexplained ataxias. 48 Although we observed a defect in mitochondrial distribution in both Drosophila neurons lacking Vps13D and patient fibroblasts containing mutations in VPS13D, the precise biological underpinnings of this defect are still under investigation, including electron microscopy studies to assess mitochondrial morphology. Alterations of mitochondrial dynamics such as transport, fission, and/or fusion 31 can all potentially manifest in aberrant distribution of mitochondria throughout the cell. Various mutations in mitochondrial genes lead to the production of reactive oxygen species, 49 which can additionally disrupt mitochondrial distribution in neurons. Combining the in vitro cellular model of patient fibroblasts and neurons differentiated from induced pluripotent stem cells with in vivo experiments in the genetic fly model may help us parse out the cellular role of VPS13D in mitochondrial biology and disease progression. These methods will also allow for testing of potential therapies that target mitochondrial dysfunction and that could be common to other forms of ataxia and spastic paraplegias.
While this article was under review, Anding et al published findings showing VPS13D to be a ubiquitinbinding protein affecting mitochondrial fission and fusion, 50 consistent with our findings, and also implemented VPS13D in autophagy, a process that we have recently reported to be involved in ataxia. We thank the patients for their willingness to participate and their patience during our research; Dr P. Capetian for clinical evaluation of Family LUB1 and for referring to the study; L. Gates, T. Kubisiak, and F. Hinrichs for excellent technical assistance; Dr J. Gudjonsson for fibroblast biopsies; S. Cho for useful discussion on VPS13 evolution; and Drs B. Post, J. Schieving, M. Jongen, and A. Shaikh for providing important clinical data.
